Holder | Position | Change | Date | |
---|---|---|---|---|
No active short positions |
Holder | Position | Change (%) | Date | |
---|---|---|---|---|
Citadel Advisors LLC | 0.42% | 22-Feb-2022 | View History | |
Citadel Advisors LLC | 0.59% | 21-Feb-2022 | View History | |
Citadel Advisors LLC | 0.48% | 07-Dec-2021 | View History | |
Citadel Advisors LLC | 0.5% | 06-Dec-2021 | View History | |
Citadel Advisors LLC | 0.39% | 19-Jan-2021 | View History | |
Citadel Advisors LLC | 0.51% | 14-Jan-2021 | View History |
Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic.
Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections.
Synairgen share price launched at 155p in 2004.